RT @PatriciaKahn: Overview of clinical evidence & obstacles to using new MDR #TB drugs (delamanid, bedaquiline) 4 patients in need https://…
RT @PatriciaKahn: Overview of clinical evidence & obstacles to using new MDR #TB drugs (delamanid, bedaquiline) 4 patients in need https://…
RT @PatriciaKahn: Overview of clinical evidence & obstacles to using new MDR #TB drugs (delamanid, bedaquiline) 4 patients in need https://…
RT @PatriciaKahn: Overview of clinical evidence & obstacles to using new MDR #TB drugs (delamanid, bedaquiline) 4 patients in need https://…
RT @PatriciaKahn: Overview of clinical evidence & obstacles to using new MDR #TB drugs (delamanid, bedaquiline) 4 patients in need https://…
Overview of clinical evidence & obstacles to using new MDR #TB drugs (delamanid, bedaquiline) 4 patients in need https://t.co/gHenxu8utz
New #TBdrugs offer hope to people with #MDRTB. Useful article by @MSF_access https://t.co/VznfPjnlqp
RT @TBbrigden: New developments in the treatment of drug-resistant tuberculosis: clin | IDR @DovePress https://t.co/WeqGApec7D
Great overview of clinical data & obstacles to using new MDR #TB drugs (delamanid, bedaquiline) 4 patients in need https://t.co/gHenxu8utz
RT @TBbrigden: New developments in the treatment of drug-resistant tuberculosis: clin | IDR @DovePress https://t.co/WeqGApec7D
RT TBbrigden New developments in the treatment of drug-resistant tuberculosis: clin | IDR DovePress https://t.co/ACHiCWkR5D
New developments in the treatment of drug-resistant tuberculosis: clin | IDR @DovePress https://t.co/WeqGApec7D